2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Purine Metabolism
  5. Hyperuricemia

Hyperuricemia

Hyperuricemia is a metabolic disorder characterized by elevated levels of uric acid in the blood, typically defined as serum uric acid concentrations exceeding 6.8 mg/dL, though diagnostic thresholds may vary by gender and age (e.g., >6 mg/dL in females, >7 mg/dL in males, and >5.5 mg/dL in youth). It arises from an imbalance between uric acid production and excretion, often due to increased purine intake, enhanced endogenous synthesis, or reduced renal excretion. This condition is associated with several clinical complications, including gout—caused by deposition of monosodium urate crystals in joints—and kidney stones, as well as long-term risks such as chronic kidney disease, cardiovascular disease, and increased cancer susceptibility. Contributing factors include genetic predisposition, diet high in purines, underlying medical conditions like kidney disease or cancer, and certain medications. While many individuals remain asymptomatic, symptoms may manifest as joint pain, swelling, and renal dysfunction. Diagnosis is confirmed through blood tests measuring serum uric acid levels.

References:

Hyperuricemia (24):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2921
    Uricase, Microorganism 9002-12-4
    Uricase, Microorganism (Uox, Microorganism) is a uricase (urate oxidase) derived from Microorganism. Uricase, Microorganism converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Microorganism can be used for research on chronic refractory gout and hyperuricemia.
    Uricase, Microorganism
  • HY-N0442
    5-O-Methylvisammioside 84272-85-5 99.90%
    5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
    5-O-Methylvisammioside
  • HY-P2921C
    Uricase (Recombinant) 9002-12-4
    Uricase (Recombinant) (Uox (Recombinant)) is a uricase (urate oxidase). Uricase (Recombinant) converts uric acid into allantoin. The deficiency of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase (Recombinant) can be used for research on chronic refractory gout and hyperuricemia.
    Uricase (Recombinant)
  • HY-147422
    Xininurad 2365178-28-3 99.59%
    Xininurad is a potent orally active URAT1 inhibitor with an IC50 of 7.17 nM. Xininurad inhibits URAT1 activity to reduce serum uric acid levels and increase urinary uric acid excretion. Xininurad can be used for the research of hyperuricemia and gout.
    Xininurad
  • HY-W075315
    Xanthine oxidoreductase-IN-6 4329-78-6 99.83%
    Xanthine oxidoreductase-IN-6 (Compound 4) is an orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 of 170 nM. Xanthine oxidoreductase-IN-6 can block the final step of uric acid biosynthesis and lower serum uric acid levels. Xanthine oxidoreductase-IN-6 also shows Cytochrome P450 3A4 (CYP3A4) inhibitory activity. Xanthine oxidoreductase-IN-6 can be used for the research of hyperuricemia.
    Xanthine oxidoreductase-IN-6
  • HY-N9783
    Procyanidin B2 3′-O-gallate 73086-04-1 98.27%
    Procyanidin B2 3′-O-gallate (B2-3′-G), isolated from Rhodiola crenulata extracts, is a potent xanthine oxidase (XO) inhibitor (IC50 = 24.24 μM, Ki = 6.16 μM). Procyanidin B2 3′-O-gallate has antioxidant activity and reduces the formation of UV-induced α-tocopheroxyl. Procyanidin B2 3′-O-gallate can be used for hyperuricemia and gout research.
    Procyanidin B2 3′-O-gallate
  • HY-181917
    Pantothenate kinase-IN-3
    Pantothenate kinase-IN-3 is an orally active PANK3-selective binder and CoA biosynthesis activator with a human PANK3 Ki of 9.1 nM, human PANK3 Ka of 1.8 nM, human PANK1β Ki of 113 nM, human PANK1β Ka of 23.4 nM, and oral effectiveness.Pantothenate kinase-IN-3 binds PANK3 via a water-mediated interaction between its sulfonamide NH and Gly193, elevates cellular, hepatic, and forebrain CoA levels, and shows improved metabolic stability in mouse and human microsomes.Pantothenate kinase-IN-3 has solubility properties favorable at pH 7.Pantothenate kinase-IN-3 can be used for the research of hepatic metabolic CoA deficiencies (acidemias).
    Pantothenate kinase-IN-3
  • HY-P2921D
    Uricase, candida utilis 9002-12-4
    Uricase, candida utilis (Uox, candida utilis) is a uricase (urate oxidase) derived from Candida utilis. Uricase, candida utilis converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, candida utilis can be used for research on chronic refractory gout and hyperuricemia.
    Uricase, candida utilis
  • HY-183543
    URAT1/GLUT9-IN-2 3051509-32-8
    URAT1/GLUT9-IN-2 (Compound 42) is a selective, orally active URAT1/GLUT9 inhibitor, with an IC50 of 2.81 μM against URAT1 and an IC50 of 12.53 μM against GLUT9. URAT1/GLUT9-IN-2 reduces serum uric acid levels and protects renal function. URAT1/GLUT9-IN-2 can be used in research related to hyperuricemia and hyperuricemic nephropathy.
    URAT1/GLUT9-IN-2
  • HY-183658
    URAT1/GLUT9-IN-3
    URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC50 values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia.
    URAT1/GLUT9-IN-3
  • HY-182000
    Xanthine oxidase-IN-23 3055112-52-9
    Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia.
    Xanthine oxidase-IN-23
  • HY-181571
    PDE4-IN-33 2545665-56-1
    PDE4-IN-33 is a phosphodiesterase 4 (PDE4) inhibitor. PDE4-IN-33 reduces uric acid levels. PDE4-IN-33 PDE4-IN-33 can be used for the research of hyperuricemia and gout.
    PDE4-IN-33
  • HY-N17914
    Smilaxchinoside A 935530-84-0
    Smilaxchinoside A is an orally active steroidal glycoside found in the roots of S. riparia. Smilaxchinoside A reduces serum uric acid levels and shows potent uricosuric activity. Smilaxchinoside A inhibits XOD activity and downregulates renal mURAT1 expression. Smilaxchinoside A can be used for the research of hyperuricemia.
    Smilaxchinoside A
  • HY-N17383
    Ligusticum cycloprolactam 2283387-37-9
    Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease.
    Ligusticum cycloprolactam
  • HY-P2921E
    Uricase, Candida sp.
    Uricase, Candida sp. (Uox, Candida sp.) is a uricase (urate oxidase) derived from Candida sp.. Uricase, Candida sp. converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Candida sp. can be used for research on chronic refractory gout and hyperuricemia.
    Uricase, Candida sp.
  • HY-180186
    Xanthine oxidase-IN-20 3069916-11-3
    Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 1.7 nM. Xanthine oxidase-IN-20 exhibits outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Xanthine oxidase-IN-20 shows favorable safety profile. Xanthine oxidase-IN-20 can be used for hyperuricemia and gout research.
    Xanthine oxidase-IN-20
  • HY-P2921B
    Uricase, Arthrobacter globiformis 9002-12-4
    Uricase, Arthrobacter globiformis (Uox, Arthrobacter globiformis) is a uricase (urate oxidase) derived from Arthrobacter globiformis. Uricase, Arthrobacter globiformis converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Arthrobacter globiformis can be used for research on chronic refractory gout and hyperuricemia.
    Uricase, Arthrobacter globiformis
  • HY-P2921A
    Uricase, Bacillus fastidious 9002-12-4
    Uricase, Bacillus fastidious (Uox, Bacillus fastidious) is a uricase (urate oxidase) derived from Bacillus fastidious. Uricase, Bacillus fastidious converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Bacillus fastidious can be used for research on chronic refractory gout and hyperuricemia.
    Uricase, Bacillus fastidious
  • HY-158161
    SLC6A19-IN-1 3032920-98-9
    SLC6A19-IN-1 is a potent and highly selective inhibitor and transport corrector of human SLC6A19 (IC50=47 nM). Furthermore, at a concentration of 35 μM, SLC6A19-IN-1 exhibits no activity against SLC1A5, SLC7A5, or SLC6A8. SLC6A19-IN-1 is applicable to research on phenylketonuria (PKU) and hyperphenylalaninemia. SLC6A19-IN-1 is also suitable for studies related to various metabolic disorders, including tyrosinemia, maple syrup urine disease, urea cycle disorders, and hyperammonemia.
    SLC6A19-IN-1
  • HY-151173
    XO/COX/LOX-IN-1 2831329-35-0
    XO/COX/LOX-IN-1 is a XO/COX/LOX inhibitor with an IC50 of 3.2 μM against rat XO, 10.83 μM against 5-LOX, 12.67 μM against COX-1, and 8.31 μM against COX-2. XO/COX/LOX-IN-1 binds to the active sites of XO, 5-LOX, COX-1 and COX-2, thereby blocking enzyme activities associated with uric acid, leukotriene, prostaglandin synthesis and inflammatory pathways. XO/COX/LOX-IN-1 can be used in the research of hyperuricemia and inflammation.
    XO/COX/LOX-IN-1